Gene Therapy Firms Including Homology Medicines Gain

Thinly traded gene therapy developer Homology Medicines (FIXX +3.6%) is up on below-average volume. Shares have rallied over 42% since touching $18.20 on November 21.

The stock debuted at $16 in late March. Lead candidate is Phase 1/2-stage HMI-102 for phenylketonuria.

Other gene therapy players in the green: (MGTX +1.9%)(GNPX +3.3%)(ABEO +4.1%)(CRSP +1.6%)(EDIT +0.4%)(NTLA +2.3%)(SRPT +2%)(ZIOP +0.3%)(RGNX +1.3%)(BMRN +0.2%)(RARE +1.1%)(VYGR +0.8%)(SGMO +1.9%)(ONCE +4.2%)(ADVM +0.8%)

https://seekingalpha.com/news/3415731-homology-medicines-4-percent